Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Maeve Waldron-Lynch rejoint Tango Therapeutics, Inc. en tant que Senior Vice President, responsable du développement clinique 06/11 CI Bourse Zurich: toujours dans le vert, après la victoire ...

(CercleFinance.com) - Le ribociclib (Kisqali®) de Novartis est reconnu comme traitement adjuvant privilégié de catégorie 1 pour le cancer du sein par les directives de pratique clinique en ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

Many drugs from different chemical classes and therapeutic areas have been shown to inhibit currents mediated via the hERG-coded ion channel, which is strongly correlated to a risk of inducing TdP.

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Expert Rev Clin Pharmacol. 2010;3(3):321-329. Despite a propensity to block hERG channel function, as determined by electrophysiology, for a limited number of compounds no cardiac arrhythmias have ...

At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...